Anika Therapeutics (ANIK) Short term Debt (2010 - 2022)

Anika Therapeutics (ANIK) has 7 years of Short term Debt data on file, last reported at $4.3 million in Q2 2022.

• On a quarterly basis, Short term Debt fell 74.42% year-over-year to $4.3 million in Q2 2022; TTM through Jun 2022 was $4.3 million, a 74.42% decrease from a year earlier, with the FY2021 full-year figure at $4.3 million, down 67.04% from the prior year.
• Short term Debt for Q2 2022 stood at $4.3 million, roughly flat from $4.3 million in the prior quarter.
• Over the last five years, Short term Debt for ANIK reached as high as $24.8 million in Q1 2021 and fell as low as $4.3 million in Q3 2021.
• Historically, Short term Debt has averaged $10.3 million across 3 years, with a median of $4.3 million in 2021.
• Across the five-year window, Short term Debt slumped 67.04% in 2021 and slumped 82.68% in 2022, its largest moves.
• Year by year, Short term Debt stood at $13.1 million in 2020, then slumped by 67.04% to $4.3 million in 2021, then changed by 0.0% to $4.3 million in 2022.
• Per Business Quant data, the three most recent Short term Debt figures were $4.3 million in Q2 2022, $4.3 million in Q1 2022, and $4.3 million in Q4 2021.